CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 112 enrolled
Drug / intervention
Isoniazid +4 moredrug
Likely dose
Metformin hydrochoride 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04930744
NCT04930744Phase 2Completed

A Prospective, Randomized Open-Label Phase II Study of the Safety and Tolerability of Metformin in Combination With Standard Antimicrobial Treatment of Pulmonary Tuberculosis in People Co-infected With HIV

University of Massachusetts, Worcester·interventional·Posted Jun 18, 2021·Updated Apr 6, 2026

In Brief

A Phase 2 clinical trial evaluating Isoniazid, Rifampicin, and 3 other interventions for Tuberculosis and 2 related conditions. Completed, enrolled 112 participants across 2 sites.

Detailed Summary

The METHOD study will examine whether adding metformin to standard antibiotic treatment for tuberculosis (TB) in people with HIV is safe and well tolerated. The study will also test if adding metformin clears the infection more quickly and with less lung damage. When enrolled, participants will have an equal chance of being in the group that takes standard TB medicines alone or in the group that also takes metformin. Participants will have a chance to be put on either: 1) standard TB medicines (isoniazid, rifampicin, ethambutol and pyrazinamide for two months, continuing isoniazid and rifampin for four more months) only; or 2) the same standard TB medicines plus metformin. Participants randomized to the metformin arm will take metformin for eleven weeks, starting one week after starting the standard TB medicines. In addition to monitoring for side effects, all participants will have studies of drug levels and lung and immune function.

Study Details

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedJun 18, 2021
Enrollment StartAug 26, 2021
Primary CompletionApr 29, 2025
Study CompletionAug 15, 2025
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 5.0 years ago

Interventions

Isoniaziddrug

Isoniazid, dose prescribed by participant's physician, will be taken by mouth daily. Isoniazid, is in a combination pill pack with the other standard ATT medications.

Rifampicindrug

Rifampicin, dose prescribed by participant's physician, will be taken by mouth daily. Rifampicin is in a combination pill pack with the other standard ATT medications.

Ethambutoldrug

Ethambutol, dose prescribed by participant's physician, will be taken by mouth daily. Ethambutol is in a combination pill pack with the other standard ATT medications.

Pyrazinamidedrug

Pyrazinamide, dose prescribed by participant's physician, will be taken by mouth daily. Pyrazinamide is in a combination pill pack with the other standard ATT medications.

Metformin hydrochoridedrug

Metformin hydrochloride 500 mg tablet once daily starting one week after the initiation of TB treatment, then increasing to twice daily through study week-12 (11 weeks total metformin treatment).